Exchange: NASDAQ·Updated 07:30 PM EDT
CLLS logo

CLLS Cellectis

$1.23
$0.01
(0.80%)
Today
Closed $1.26
$0.0301
(2.39%)
After Hours
EarningsNov 13
Mkt Cap$91.13M
Vol75,759.00

About CLLS

Cellectis SA operates as a clinical stage biotechnological company, which engages in gene-editing platform to develop cell and gene therapies. The company was founded by David J. Sourdive and André Choulika on February 20, 1999 and is headquartered in Paris, France.
40

Bearish Sentiment

How do you feel about CLLS?

briefingcom
$CLLS: Cellectis (-20.3%) approved a strategic transformation to become an in vivo gene editing company focused on developing long-lasting treatments for chronic diseases.
2
caronte
$CLLS I believe with such good value for money (its target price is 30$+) will be a buying target for astrazeneca (which is already a main shareholder)
1
rlkloehn
$CLLS The Law Offices of Frank R. Cruz and the office of Howard G. Smith) have announced an investigation into potential infringement of federal securities laws targeting Cellectis S.A. (CLLS)
1
StocktwitsNews
CLLS Stock Heads For 14-Month Low After 40% Rout: Citizens Flags Delayed Cellectis Catalysts After Cancer Pipeline Pivot $CLLS $ALLO $AZN $IOVA https://stocktwits.com/news/equity/markets/clls-stock-cellectis-cancer-pivot-citizens-downgrade/cZtneLBRBTz
1
Bigbossmann
$CLLS Not even 1% of the OS shares have traded today, lol. Watch this blow to the moon at EOD!
1
focafoca99
$CLLS has shifted to an in-vivo gene-editing focus, exiting its CAR-T assets and targeting HEAL-101/HEAL-201.
1
rlkloehn
$CLLS today announced that it will host a conference call and webcast on Monday, September 14, 2026 to provide a business update
1
Invescent
📉 $CLLS Top Loser #3 Move: down 39.1% 🔴 Financial Health: Weak • 0/100 🔴 Cash Flow Strength: Weak • Free cash flow -$42.50M 🔴 Profitability: Weak • Net margin -92.7% 🟡 Valuation: Not Meaningful • P/E is not meaningful because earnings are negative; P/S is 6.52 Analysis: Cellectis S. A. Not financial advice.

Advertisement|Remove ads.